文献速递妇科肿瘤

ICON8:上皮性卵巢癌、输卵管癌或原发性腹膜癌一线周剂量密集化疗的总生存结果:一项开放标签、随机、对照、3期试验

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2022-06-09

ICON8研究纳入1566例新诊断上皮性卵巢癌、原发性腹膜癌或输卵管癌患者,随机分为3周卡铂联合3周紫杉醇组(组1)、3周卡铂联合周紫杉醇组(组2)和周卡铂联合周紫杉醇组(组3)。中位随访69个月,组2与组1、组3与组1的总生存和无进展生存均无显著差异,周剂量密集化疗不应作为该患者群体标准多模式一线治疗的一部分。

要点

  • 周剂量密集化疗(组2、组3)较标准3周方案(组1)未改善总生存和无进展生存。
  • 组2 vs 组1总生存HR 0.87(97.5%CI 0.73-1.05),组3 vs 组1 HR 0.91(0.76-1.09)。
  • 周剂量密集组3-4级中性粒细胞减少和贫血发生率高于标准组。

核心结论

  • 在主要为欧洲女性的上皮性卵巢癌队列中,一线周剂量密集化疗与标准3周化疗相比未改善总生存或无进展生存,不应作为该患者群体标准多模式一线治疗的一部分。

研究设计与样本

  • 开放标签、随机、对照、3期试验(ICON8),在英国、澳大利亚和新西兰、墨西哥、韩国和爱尔兰的117家有肿瘤科病房的医院招募18岁及以上新诊断FIGO 1988标准IC-IV期上皮性卵巢癌、原发性腹膜癌或输卵管癌且ECOG体能状态0-2的患者。
  • 患者可在立即初次手术后、计划延迟初次手术期间或无计划手术情况下入组,按1:1:1随机分配至组1(3周卡铂AUC5或AUC6联合3周紫杉醇175 mg/m2)、组2(3周卡铂AUC5或AUC6联合周紫杉醇80 mg/m2)或组3(周卡铂AUC2联合周紫杉醇80 mg/m2),均静脉输注共6个21天周期。
  • 共同主要终点为无进展生存和总生存,在意向治疗人群中比较组2与组1、组3与组1;安全性在所有至少开始一个化疗周期的患者中评估。
  • 2011年6月6日至2014年11月28日共随机分配1566例患者:组1 522例、组2 523例、组3 521例;中位年龄62岁(IQR 54-68),1073例(69%)为高级别浆液性癌,1119例(71%)为IIIC-IV期,745例(48%)接受立即初次手术。

主要发现

  • 截至数据截止日2020年3月31日,中位随访69个月(IQR 61-75),总生存无显著差异:组1中位47.4个月(95%CI 43.1-54.8),组2 54.8个月(46.6-61.6),组3 53.4个月(49.2-59.6)。
  • 组2 vs 组1总生存HR 0.87(97.5%CI 0.73-1.05),组3 vs 组1 HR 0.91(0.76-1.09)。
  • 无进展生存两组比较均无显著差异,且存在非比例风险证据(p=0.037),限制性平均生存时间:组1 23.9个月(97.5%CI 22.1-25.6),组2 25.3个月(23.6-27.1),组3 24.8个月(23.0-26.5)。
  • 最常见3-4级不良事件为中性粒细胞减少(组1 78/511例[15%]、组2 183/514例[36%]、组3 154/513例[30%])、白细胞减少(组1 22例[4%]、组2 80例[16%]、组3 71例[14%])和贫血(组1 26例[5%]、组2 66例[13%]、组3 24例[5%])。
  • 未报告新的严重不良事件;报告7例治疗相关死亡(组1 2例、组2 4例、组3 1例)。

关键数值与推荐

  • 组1(对照):3周卡铂AUC5或AUC6联合3周紫杉醇175 mg/m2,共6个21天周期。
  • 组2:3周卡铂AUC5或AUC6联合周紫杉醇80 mg/m2,共6个21天周期。
  • 组3:周卡铂AUC2联合周紫杉醇80 mg/m2,共6个21天周期。

临床怎么用

  • 作者结论认为,一线周剂量密集化疗不应作为该患者群体标准多模式一线治疗的一部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly (ie, once every 3 weeks) carboplatin. However, this benefit was not observed in the previously reported progression-free survival results of ICON8. Here, we present the final coprimary outcomes of overall survival and updated progression-free survival analyses of ICON8. METHODS: In this open-label, randomised, controlled, phase 3 trial (ICON8), women aged 18 years or older with newly diagnosed stage IC-IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma (here collectively termed ovarian cancer, as defined by International Federation of Gynecology and Obstetrics [FIGO] 1988 criteria) and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited from 117 hospitals with oncology departments in the UK, Australia and New Zealand, Mexico, South Korea, and Ireland. Patients could enter the trial after immediate primary surgery (IPS) or with planned delayed primary surgery (DPS) during chemotherapy, or could have no planned surgery. Participants were randomly assigned (1:1:1), using the Medical Research Council Clinical Trials Unit at University College London randomisation line with stratification by Gynecologic Cancer Intergroup group, FIGO disease stage, and outcome and timing of surgery, to either 3-weekly carboplatin area under the curve (AUC)5 or AUC6 and 3-weekly paclitaxel 175 mg/m2 (control; group 1), 3-weekly carboplatin AUC5 or AUC6 and weekly paclitaxel 80 mg/m2 (group 2), or weekly carboplatin AUC2 and weekly paclitaxel 80 mg/m2 (group 3), all administered via intravenous infusion for a total of six 21-day cycles. Coprimary outcomes were progression-free survival and overall survival, with comparisons done between group 2 and group 1, and group 3 and group 1, in the intention-to-treat population. Safety was assessed in all patients who started at least one chemotherapy cycle. The trial is registered on ClinicalTrials.gov, NCT01654146, and ISRCTN registry, ISRCTN10356387, and is closed to accrual. FINDINGS: Between June 6, 2011, and Nov 28, 2014, 1566 patients were randomly assigned to group 1 (n=522), group 2 (n=523), or group 3 (n=521). The median age was 62 years (IQR 54-68), 1073 (69%) of 1566 patients had high-grade serous carcinoma, 1119 (71%) had stage IIIC-IV disease, and 745 (48%) had IPS. As of data cutoff (March 31, 2020), with a median follow-up of 69 months (IQR 61-75), no significant difference in overall survival was observed in either comparison: median overall survival of 47·4 months (95% CI 43·1-54·8) in group 1, 54·8 months (46·6-61·6) in group 2, and 53·4 months (49·2-59·6) in group 3 (group 2 vs group 1: hazard ratio 0·87 [97·5% CI 0·73-1·05]; group 3 vs group 1: 0·91 [0·76-1·09]). No significant difference was observed for progression-free survival in either comparison and evidence of non-proportional hazards was seen (p=0·037), with restricted mean survival time of 23·9 months (97·5% CI 22·1-25·6) in group 1, 25·3 months (23·6-27·1) in group 2, and 24·8 months (23·0-26·5) in group 3. The most common grade 3-4 adverse events were reduced neutrophil count (78 [15%] of 511 patients in group 1, 183 [36%] of 514 in group 2, and 154 [30%] of 513 in group 3), reduced white blood cell count (22 [4%] in group 1, 80 [16%] in group 2, and 71 [14%] in group 3), and anaemia (26 [5%] in group 1, 66 [13%] in group 2, and 24 [5%] in group 3). No new serious adverse events were reported. Seven treatment-related deaths were reported (two in group 1, four in group 2, and one in group 3). INTERPRETATION: In our cohort of predominantly European women with epithelial ovarian cancer, we found that first-line weekly dose-dense chemotherapy did not improve overall or progression-free survival compared with standard 3-weekly chemotherapy and should not be used as part of standard multimodality front-line therapy in this patient group. FUNDING: Cancer Research UK, Medical Research Council, Health Research Board in Ireland, Irish Cancer Society, and Cancer Australia.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2022. PMID: 35690073. doi:10.1016/S1470-2045(22)00283-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。